Grand Pharmaceutical's TP-03 Ophthalmic Solution Reaches First Commercial Prescriptions in China
Start here
Grand Pharmaceutical Group (0512.HK) has recorded the first commercial prescriptions of Manmu'an (TP-03, lotilaner ophthalmic solution 0.25%) in mainland China, delivering the product to 11 medical institutions across Beijing, Shanghai, Guangdong, Tianjin, Chongqing, Zhejiang, Fujian, Hubei and Shaanxi. The drug treats demodex blephitis, and the source describes it as the first and only approved product for this indication in Greater China. The reference product posted US sales of about $450 million in 2025 and about $320 million in the first half of 2026, suggesting a substantial market opportunity. What remains open is how quickly prescriptions and sales ramp up across China beyond the initial 11 hospitals and additional regions.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatGrand Pharmaceutical's TP-03 Ophthalmic Solution Reaches First Commercial Prescriptions at 11 Mainland China Hospitals
Grand Pharmaceutical Group (0512.HK) has delivered the first commercial prescriptions of its ophthalmic product Manmu'an (TP-03, lotilaner ophthalmic solution 0.25%) in mainland China, at 11 medical institutions across Beijing, Shanghai, Guangdong, Tianjin, Chongqing, Zhejiang, Fujian, Hubei and Shaanxi, for demodex blepharitis. The source calls it the first and only approved product for this indication in Greater China, and reports US sales of about $450 million in 2025 and about $320 million in the first half of 2026.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 20 09:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.